Olema Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Olema Pharmaceuticals, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Revenue & Gross Profit
Revenue0.000.000.000.000.00
Cost of Revenue0.000.000.000.000.00
Gross Profit0.000.000.000.000.00
Operating Expenses
Research & Development124.5286.1482.2751.1013.70
Selling, General & Administrative17.7418.8224.7120.397.82
Operating Expenses142.26104.96106.9971.4921.53
Operating Income-142.26-104.96-106.99-71.49-21.53
Other Income/Expense
Interest Income12.688.332.230.440.06
Interest Expense0.000.000.000.00-0.65
Other Income/Expense12.78-0.02-0.03-0.050.00
Income
Income Before Tax-129.47-96.66-104.79-71.10-22.12
Income Tax Expense0.00-6.13-6.68-0.030.00
Net Income-129.47-96.66-104.79-71.10-22.12
Net Income - Continuous Operations-129.47-96.66-104.79-71.100.00
Net Income - Discontinued Operations0.000.000.000.000.00
EBITDA-141.87-104.58-106.63-71.33-21.52
EBIT-138.02-104.96-106.99-71.49-21.53
Depreciation & Amortization0.390.380.360.160.01
Earnings Per Share
Basic EPS-2.00-2.00-3.00-2.00-3.00
Diluted EPS-2.00-2.00-3.00-2.00-3.00
Basic Shares Outstanding58.7445.2540.0039.527.02
Diluted Shares Outstanding58.7445.2540.0039.527.02